{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T14:35:51Z","timestamp":1779028551777,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"DOI":"10.7759\/cureus.105749","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:27:53Z","timestamp":1774348073000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study)"],"prefix":"10.7759","author":[{"given":"Nitin","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arindam","family":"Naskar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehla","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sambit","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Kota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saptarshi","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raja","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niteen","family":"Karnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gandhi","family":"Parise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Mangipudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amritava","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amol","family":"Dange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayura","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narayan","family":"Deogaonkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paramesh","family":"Shamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanket","family":"Sorate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Saklecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheloje","family":"Samadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Varade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayashree","family":"Shembalkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kushal","family":"Bangar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Lomte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayur","family":"Mayabhate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin","family":"Kapure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akhilesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhakrishna","family":"Vaddem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Health Organization. Obesity and overweight. (2025). Accessed. January 2026, 2025:  https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/0972753120987465","article-title":"Prevalence of obesity in India and its neurological implications: a multifactor analysis of a nationwide cross-sectional study","volume":"27","author":"Venkatrao M","year":"2020","unstructured":"Venkatrao M, Nagarathna R, Majumdar V, Patil SS, Rathi S, Nagendra H. Prevalence of obesity in India and its neurological implications: a multifactor analysis of a nationwide cross-sectional study. Ann Neurosci. 2020, 27:153-61. 10.1177\/0972753120987465","journal-title":"Ann Neurosci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.115.306883","article-title":"Obesity and cardiovascular disease","volume":"118","author":"Ortega FB","year":"2016","unstructured":"Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016, 118:1752-70. 10.1161\/CIRCRESAHA.115.306883","journal-title":"Circ Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing RR","year":"2013","unstructured":"Wing RR, Bolin P, Brancati FL, et al.. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013, 369:145-54. 10.1056\/NEJMoa1212914","journal-title":"N Engl J Med"},{"key":"ref5","article-title":"Psychological issues associated with obesity","author":"Segal Y","year":"2025","unstructured":"Segal Y, Gunturu S. Psychological issues associated with obesity. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/87551225221092681","article-title":"Once-weekly semaglutide for weight management: a clinical review","volume":"38","author":"Fornes A","year":"2022","unstructured":"Fornes A, Huff J, Pritchard RI, Godfrey M. Once-weekly semaglutide for weight management: a clinical review. J Pharm Technol. 2022, 38:239-46. 10.1177\/87551225221092681","journal-title":"J Pharm Technol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2021.12.008","article-title":"Semaglutide for the treatment of obesity","volume":"33","author":"Chao AM","year":"2023","unstructured":"Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023, 33:159-66. 10.1016\/j.tcm.2021.12.008","journal-title":"Trends Cardiovasc Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton S","year":"2020","unstructured":"Wharton S, Lau DC, Vallis M, et al.. Obesity in adults: a clinical practice guideline. CMAJ. 2020, 192:E875-91. 10.1503\/cmaj.191707","journal-title":"CMAJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk V","year":"2015","unstructured":"Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, Toplak H. European guidelines for obesity management in adults. Obes Facts. 2015, 8:402-24. 10.1159\/000442721","journal-title":"Obes Facts"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity","volume":"22 Suppl 3","author":"Garvey WT","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, et al.. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for medical care of patients with obesity. Endocr Pract. 2016, 22 Suppl 3:1-203. 10.4158\/EP161365.GL","journal-title":"Endocr Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10816","article-title":"Medications for obesity: a review","volume":"332","author":"Gudzune KA","year":"2024","unstructured":"Gudzune KA, Kushner RF. Medications for obesity: a review. JAMA. 2024, 332:571-84. 10.1001\/jama.2024.10816","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103020","article-title":"Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living\u00a0with overweight or obesity: a systematic review and meta-analysis","volume":"79","author":"Liu L","year":"2025","unstructured":"Liu L, Li Z, Ye W, et al.. Safety and effects of anti-obesity medications on weight loss, cardiometabolic, and psychological outcomes in people living\u00a0with overweight or obesity: a systematic review and meta-analysis. EClinicalMedicine. 2025, 79:103020. 10.1016\/j.eclinm.2024.103020","journal-title":"EClinicalMedicine"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan DH","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, et al.. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024, 30:2049-57. 10.1038\/s41591-024-02996-7","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.04.041","article-title":"Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"222","author":"Moiz A","year":"2024","unstructured":"Moiz A, Levett JY, Filion KB, Peri K, Reynier P, Eisenberg MJ. Long-term efficacy and safety of once-weekly semaglutide for weight loss in patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiol. 2024, 222:121-30. 10.1016\/j.amjcard.2024.04.041","journal-title":"Am J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell J","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017, 19:1242-51. 10.1111\/dom.12932","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen M","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021, 23:754-62. 10.1111\/dom.14280","journal-title":"Diabetes Obes Metab"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery S","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ, et al.. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020, 5:10.1172\/jci.insight.133429","journal-title":"JCI Insight"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen LB","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019, 10:155. 10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing RR","year":"2011","unstructured":"Wing RR, Lang W, Wadden TA, et al.. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011, 34:1481-6. 10.2337\/dc10-2415","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21358","article-title":"Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?","volume":"23","author":"Williamson DA","year":"2015","unstructured":"Williamson DA, Bray GA, Ryan DH. Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?. Obesity (Silver Spring). 2015, 23:2319-20. 10.1002\/oby.21358","journal-title":"Obesity (Silver Spring)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.02.005","article-title":"Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity","volume":"23","author":"Magkos F","year":"2016","unstructured":"Magkos F, Fraterrigo G, Yoshino J, et al.. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016, 23:591-601. 10.1016\/j.cmet.2016.02.005","journal-title":"Cell Metab"},{"key":"ref23","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","year":"2016","unstructured":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes. a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016, 4:913-21.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.ijem_217_22","article-title":"First-in-class oral semaglutide: overcoming barriers of incretinisation in the Indian context","volume":"26","author":"Rajput R","year":"2022","unstructured":"Rajput R, Ghosh S, Banerjee S, et al.. First-in-class oral semaglutide: overcoming barriers of incretinisation in the Indian context. Indian J Endocrinol Metab. 2022, 26:417-27. 10.4103\/ijem.ijem_217_22","journal-title":"Indian J Endocrinol Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.r1606","article-title":"Side effects of GLP-1 receptor agonists","volume":"390","author":"Manne-Goehler J","year":"2025","unstructured":"Manne-Goehler J, Franco J. Side effects of GLP-1 receptor agonists. BMJ. 2025, 390:r1606. 10.1136\/bmj.r1606","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4103\/JNMO.JNMO_55_25","article-title":"Injectable semaglutide (Wegovy) in India: promise, pitfalls and the way forward","volume":"19","author":"Kaliya M","year":"2025","unstructured":"Kaliya M, Rathod M. Injectable semaglutide (Wegovy) in India: promise, pitfalls and the way forward. NMO J. 2025, 19:220-1. 10.4103\/JNMO.JNMO_55_25","journal-title":"NMO J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/473049-comparative-efficacy-and-safety-of-once-weekly-semaglutide-formulations-in-indian-adults-with-obesity-a-phase-iii-randomized-non-inferiority-active-controlled-study-size-plus-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T10:27:55Z","timestamp":1774348075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/473049-comparative-efficacy-and-safety-of-once-weekly-semaglutide-formulations-in-indian-adults-with-obesity-a-phase-iii-randomized-non-inferiority-active-controlled-study-size-plus-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.105749","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}